Feasibility of home-based exercise training in men with metastatic castration-resistant prostate cancer

被引:10
|
作者
Hanson, Erik D. [1 ,2 ]
Alzer, Mohamdod [1 ]
Carver, Jackson [1 ]
Stopforth, Cameron K. [1 ]
Lucas, Alexander R. [3 ,4 ]
Whang, Young E. [2 ,5 ]
Milowsky, Matthew, I [2 ,5 ]
Bartlett, David B. [6 ,7 ]
Harrison, Michael R. [6 ]
Bitting, Rhonda L. [3 ]
Deal, Allison M. [2 ]
Stoner, Lee [1 ]
Hackney, A. C. [1 ,8 ]
Battaglini, Claudio L. [1 ,2 ]
机构
[1] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC 27515 USA
[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA
[3] Wake Forest Baptist Comprehens Canc Ctr, Winston Salem, NC USA
[4] Virginia Commonwealth Univ, Dept Hlth Behav & Policy, Richmond, VA USA
[5] Univ N Carolina, Dept Med, Div Oncol, Chapel Hill, NC USA
[6] Duke Univ, Duke Canc Inst, Div Med Oncol, Durham, NC USA
[7] Univ Surrey, Fac Hlth & Med Sci, Sch Biosci & Med, Guildford, Surrey, England
[8] Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC USA
关键词
ANDROGEN-DEPRIVATION THERAPY; QUALITY-OF-LIFE; PHYSICAL FUNCTION; BODY-COMPOSITION; FUNCTIONAL ASSESSMENT; CLINICAL-TRIAL; STRENGTH; ENZALUTAMIDE; ABIRATERONE; PROGRAM;
D O I
10.1038/s41391-022-00523-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Home-based training increases accessibility to exercise and mitigates the side effects of hormone therapy for prostate cancer (PC). However, it is unknown if men with more advanced disease are willing to partake in such interventions. Purpose To determine the feasibility of a home-based exercise intervention in men with metastatic castration-resistant prostate cancer (mCRPC). Methods mCRPC patients on androgen receptor signaling inhibitors (ARSI) were prescribed a 12-week, home-based exercise intervention using resistance bands and walking. Feasibility was assessed using recruitment, retention, adherence, and outcome capture. Physiological changes and patient reported outcomes were assessed before and after the intervention. Results Of the 62 referrals, 47 were eligible with 22 men performing baseline testing (47% recruitment rate) and 16 completing the intervention (73% retention). Task completion was >86% for all physiological tests. Walking adherence was 80% and resistance training was 63%, the latter falling short of the study target (75%). Training increased thigh muscle cross-sectional area by 22%, time to exhaustion by 19% (both p < 0.05) and peak oxygen uptake by 6% (p = 0.057). Improvements in short physical performance battery scores and 400 m walk demonstrated moderate effect sizes that did not reach significance. Conclusions Home-based exercise is feasible during ARSI treatment for mCRPC. Greater endurance capacity and localized hypertrophy appear as the primary improvements following training. These preliminary findings suggest home-based training may increase exercise accessibility, with important lessons that will inform subsequent trials investigating the efficacy of home-based exercise interventions during mCRPC.
引用
收藏
页码:302 / 308
页数:7
相关论文
共 50 条
  • [31] Treatment decision-making and treatment experiences in men with metastatic castration-resistant prostate cancer
    Doveson, Sandra
    Fransson, Per
    Axelsson, Lena
    Wennman-Larsen, Agneta
    ACTA ONCOLOGICA, 2025, 64 : 462 - 469
  • [32] Incidence and Correlates of Fatigue in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review
    Colloca, Giuseppe
    Venturino, Antonella
    Governato, Ilaria
    Checcaglini, Franco
    CLINICAL GENITOURINARY CANCER, 2016, 14 (01) : 5 - 11
  • [33] Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer
    Graff, Julie N.
    Beer, Tomasz M.
    ONCOLOGY-NEW YORK, 2015, 29 (06): : 416 - 423
  • [34] Abiraterone in the treatment of metastatic castration-resistant prostate cancer
    Mostaghel, Elahe A.
    CANCER MANAGEMENT AND RESEARCH, 2014, 6 : 39 - 51
  • [35] Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer
    de la Maza, Maria Dolores Fenor
    Chandran, Khobe
    Rekowski, Jan
    Shui, Irene M.
    Gurel, Bora
    Cross, Emily
    Carreira, Suzanne
    Yuan, Wei
    Westaby, Daniel
    Miranda, Susana
    Ferreira, Ana
    Seed, George
    Crespo, Mateus
    Figueiredo, Ines
    Bertan, Claudia
    Gil, Veronica
    Riisnaes, Ruth
    Sharp, Adam
    Rodrigues, Daniel Nava
    Rescigno, Pasquale
    Tunariu, Nina
    Liu, Xiao Qiao
    Cristescu, Razvan
    Schloss, Charles
    Yap, Christina
    Bono, Johann S. de
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (06): : 659 - 667
  • [36] Olaparib for Metastatic Castration-Resistant Prostate Cancer REPLY
    de Bono, Johann
    Kang, Jinyu
    Hussain, Maha
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (09): : 891 - 891
  • [37] Abiraterone AcetateIn Metastatic Castration-Resistant Prostate Cancer
    Lily P. H. Yang
    Drugs, 2011, 71 : 2067 - 2077
  • [38] Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer
    Merseburger, Axel S.
    Bellmunt, Joaquim
    Jenkins, Cheryl
    Parker, Chris
    Fitzpatrick, John M.
    ONCOLOGIST, 2013, 18 (05): : 558 - 567
  • [39] Improving quality of life in metastatic castration-resistant prostate cancer: the role of androgen receptor axis-targeted agents
    Kuzma, Monika
    Breznicka, Maria
    Kliment, Jan
    JOURNAL OF MENS HEALTH, 2023, 19 (07) : 1 - 7
  • [40] Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer
    Zhang, Tian
    Zhu, Jason
    George, Daniel J.
    Armstrong, Andrew J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (04) : 473 - 485